The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Pregabalin Pharmacology and Its Relevance to Clinical Practice
Abstract
Summary: Pregabalin is a potent ligand for the alpha‐2‐delta subunit of voltage‐gated calcium channels in the central nervous system that exhibits potent anticonvulsant, analgesic, and anxiolytic activity in a range of animal models. In addition, pregabalin has been shown to be a highly effective adjunctive therapy for partial seizures in clinical trials. Potent binding to the alpha‐2‐delta site reduces depolarization‐induced calcium influx with a consequential modulation in excitatory neurotransmitter release. Pregabalin has no demonstrated effects on GABAergic mechanisms. Pregabalin demonstrates highly predictable and linear pharmacokinetics, a profile that makes it easy to use in clinical practice. Absorption is extensive, rapid, and proportional to dose. Time to maximal plasma concentration is ∼1 h and steady state is achieved within 24–48 h. These characteristics reflect the observed onset of efficacy as early as day two in clinical trials. High bioavailability, a mean elimination half life (t 1/2) of 6.3 h, and dose‐proportional maximal plasma concentrations and total exposures predict a dose–response relationship in clinical practice and allow an effective starting dose of 150 mg/day in clinical practice without need for titration. Administration with food has no clinically relevant effect on the amount of pregabalin absorbed, providing for a dosing regimen uncomplicated by meals. Pregabalin does not bind to plasma proteins and is excreted virtually unchanged (<2% metabolism) by the kidneys. It is not subject to hepatic metabolism and does not induce or inhibit liver enzymes such as the cytochrome P450 system. Therefore, pregabalin is unlikely to cause, or be subject to, pharmacokinetic drug–drug interactions—an expectation that has been confirmed in clinical pharmacokinetic studies. However, dose adjustment may be necessary in patients with renal insufficiency. Thus, the pharmacological and pharmacokinetic profiles of pregabalin provide a predictable basis for its use in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Early Identification of Refractory Epilepsy
Kwan, P., & Brodie, M. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002033420503 · Cited by 5,204
Cited by
Efficacy of pregabalin in acute postoperative pain: a meta-analysis
Zhang, J., Ho, K.-Y., & Wang, Y. (2011) · British Journal of Anaesthesia · doi:10.1093/bja/aer027 · Cited by 357
Trial of pregabalin for acute and chronic sciatica
Mathieson, S., Maher, C. G., McLachlan, A. J., Latimer, J., Koes, B. W., Hancock, M. J., Harris, I., Day, R. O., Billot, L., Pik, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614292 · Cited by 219
Houghton, L. A., Fell, C., Whorwell, P. J., Jones, I., Sudworth, D. P., & Gale, J. D. (2007) · Gut · doi:10.1136/gut.2006.110858 · Cited by 204
Pregabalin: A Review of its Use in Fibromyalgia
Lyseng-Williamson, K. A., & Siddiqui, M. A. A. (2008) · Drugs · doi:10.2165/00003495-200868150-00009 · Cited by 50
Ghumman, S. A., Bashir, S., Noreen, S., Khan, A. M., & Malik, M. Z. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.08.100 · Cited by 39
Metadata
- Authors
- Ben‐Menachem, E.
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 2004-08
- Volume
- 45
- Issue
- s6
- Pages
- 13-18
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W2076516150
- Cited by
- 542
- References
- 1
- FWCI
- 10.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pregabalin Pharmacology and Its Relevance to Clinical Practice. https://app.cochat.ai/papers/10.1111/j.0013-9580.2004.455003.x
- The paper
- Ben‐Menachem, E. (2004). Pregabalin Pharmacology and Its Relevance to Clinical Practice. Epilepsia. https://doi.org/10.1111/j.0013-9580.2004.455003.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.